1. In Vivo

Can Modicare Reshape India’s Health Care Paradigm?

 
• By Anju Ghangurde

India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?

Modicare
India’s mammoth health assurance scheme offers hope of better health care for over 100 million families • Source: Shutterstock

An auto rickshaw driver who suffered a heart attack but could not afford surgery was the first beneficiary from the state of Haryana to undergo an angioplasty under India’s Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY). In another case, a wage labourer in Uttar Pradesh state, underwent a free cholecystectomy to get a stone removed from his gall bladder.

Many such heart-warming stories featured in recent tweets by Dr. Indu Bhushan, the man at the helm of seeing through the implementation of PMJAY, India’s mammoth health assurance scheme that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.